A proof-of-concept study designed to test a new tablet formulation of the experimental therapy ANX1502 in people with cold…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Riliprubart (SAR445088), a potential successor to Enjaymo (sutimlimab-jome) as a cold agglutinin disease (CAD) treatment, may achieve therapeutic…
Nearly half of people without symptoms of cold agglutinin disease (CAD) who undergo a lung transplant test positive for cold…
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale, a widely used questionnaire to assess fatigue, is reliable, valid, and…
Annexon Biosciences’ new tablet formulation of its experimental therapy ANX1502 reduced key clinical and biomarker measures in the three…
Nearly half of children and teens with autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold…
Clinicians detected B-cell lymphoma, a type of blood cancer, in a 53-year-old man two years after he was diagnosed with…
A boy in China was diagnosed with a rare case of cold agglutinin disease (CAD) associated with a…
Researchers said a case of cold agglutinin disease (CAD) in a 92-year-old man in Pakistan illustrates the challenges of…
A 50-year-old woman developed cold agglutinin disease (CAD) secondary to two different types of cancer within the thyroid gland, a…